AM-AF study

The effects of adrenomedullin for catheter ablation of patients with persistent atrial fibrillation - AM-AF study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071190005

Enrollment

Registered

2019-04-26

Start date

2019-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation atrial fibrillation

Interventions

adrenomedullin arm: adrenomedullin continuous venous infusion (10 ng/kg/min, 8 hours per day) given from the day before catheter ablation to after three days of ablation (total 5 days) control arm: ca

adrenomedullin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient receiving catheter ablation for persistent atrial fibrillation

Exclusion criteria

Exclusion criteria: 1. paroxysmal atrial fibrillation 2. significant valvular disease 3. significant heart disease (heart failure, myocardial infarction, angina etc.) 4. hyperthyroidism 5. diameter of left atria over 50 mm 6. active infection or inflammatory disease 7. malignancy

Design outcomes

Primary

Measure	Time frame
Total time of significant atrial arrhythmias within 3 days after catheter ablation	—

Secondary

Measure	Time frame
1. rate of atrial arrhythmias within 3 days after catheter ablation 2. rate of atrial arrhythmias from 4 to 14 days after catheter ablation 3. inflammatory makers 4. adverse event	—

Contacts

Public ContactToshihiro Kita

University of Miyazaki Hospital

toshihiro_kita@med.miyazaki-u.ac.jp+81-985-85-0872

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026